Drug intelligence / Profile preview

DESF

Development stage: Phase 2
Lead developer: Aquestive Therapeutics
Administration: Sublingual

Overview

DESF is an investigational drug developed by Aquestive Therapeutics. It is being evaluated in a Phase 2 clinical trial for the treatment of Oral Allergy Syndrome (OAS). The drug is administered in the sublingual space, and the study aims to evaluate the pharmacokinetics and pharmacodynamics of epinephrine after single and repeat doses of DESF.

Targets

AR (Adrenergic receptors)

Beyond the preview

Go deeper on DESF.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DESF.

Explore the full profile